Objective Sac shrinkage is considered a reliable surrogate marker of success after
endovascular aneurysm repair (EVAR). Whereas sac shrinkage is the best expected …

Background: Abdominal aortic aneurysm (AAA), a common disease involving the segmental
expansion and rupture of the aorta, has a high mortality rate. Therapeutic options for AAA …

Objective The midterm results of endovascular abdominal aortic aneurysm repair (EVAR)
with aortic side branch coil embolization during EVAR was evaluated. Methods Our center …

Tranexamic acid reduces blood loss and transfusion requirements with no significant
thrombotic adverse effects. Postoperative seizures have been seen in cardiac surgical …

Objectives: Aneurysm shrinkage after EVAR is the strong factor of favorable outcomes after
endovascular abdominal aortic aneurysm repair (EVAR), and type II endoleaks is the risk …

Tranexamic acid: from trauma to routine perioperative use : Current Opinion in
Anesthesiology Tranexamic acid: from trauma to routine perioperative use : Current Opinion …

Introduction Type II endoleak (EL) is frequently seen after endovascular aneurysm repair
(EVAR) for abdominal aortic aneurysm (AAA) and is often considered responsible for …

Objective Endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) has
gained widespread use through a solid reputation of safety and effectiveness. However …

Background Sac regression after endovascular aneurysm repair (EVAR) of abdominal aortic
aneurysms (AAA) is regarded as a marker of successful response to treatment. Several …

Tranexamic acid (TXA) is an antifibrinolytic drug which has been widely used in many areas
of surgery. The purpose of our meta-analysis was to review randomized controlled trials …